Pipeline
Cellantratech is advancing two preclinical oncology co-lead programs supported by a reusable nonviral delivery platform and research-stage in vivo engineered-TCR programs.
DEVELOPMENT APPROACH
A Common Validation Framework Guides Program Decisions
Programs advance through repeatable evidence categories—access, delivery and expression, and function and safety—so development decisions remain comparable across modalities.
Access
Evaluate target recognition, specificity and accessibility in the intended disease compartment.
Delivery & Expression
Evaluate target-dependent uptake or expression, payload integrity, and delivery in the intended cell population.
Function & Safety
Assess target engagement, disease-relevant function, and potential off-target or safety signals.
Independent Confirmation
Confirm key findings through reproducible studies before advancing a program to the next development stage.
Our Values
Congue ultric in pellentesque sodales egestas faucibus accumsan.
01.
Discovery
Programs begin with a biological thesis and progress toward a prioritized candidate or product concept.
02.
Preclinical Validation
Programs advance when internal evidence supports a prioritized lead and readiness for confirmatory development work.
03.
Confirmatory Development
Confirmatory studies strengthen the evidence package and support decisions about progression toward IND-enabling work.
04.
IND-Enabling Development
IND-enabling work integrates nonclinical, manufacturing and regulatory activities toward a filing-readiness package.
05.
Filing Readiness
A filing-readiness package brings together the evidence needed to support a potential regulatory submission.
06.
Portfolio Expansion
New concepts remain outside the active lead-development plan until they meet defined feasibility and evidence gates.
